
Cue Biopharma Market Cap | CUE
As of November 22, 2026 Cue Biopharma has a market cap of $ 398 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Cue Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.4 M | 51.3 M | 86.5 M | 108 M | 354 M | 388 M | 337 M | 101 M | 311 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 388 M | 29.4 M | 196 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Reata Pharmaceuticals
RETA
|
1.64 B | - | - | $ 6.29 B | ||
|
PainReform Ltd.
PRFX
|
1.72 M | $ 0.47 | -24.53 % | $ 305 K | ||
|
iTeos Therapeutics
ITOS
|
293 M | - | - | $ 411 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 1.44 | -2.03 % | $ 2.37 M | ||
|
PolarityTE
PTE
|
4.32 M | - | -0.82 % | $ 1.78 M | ||
|
Kronos Bio
KRON
|
69.3 M | - | 1.49 % | $ 50.8 M | ||
|
Cullinan Management
CGEM
|
898 M | $ 8.9 | -1.93 % | $ 536 M | ||
|
CRISPR Therapeutics AG
CRSP
|
4.39 B | $ 39.15 | 0.57 % | $ 3.52 B | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
2.01 B | $ 26.77 | -0.59 % | $ 1.59 B | ||
|
Trevena
TRVN
|
5.09 M | - | -46.58 % | $ 31.8 M | ||
|
Calithera Biosciences
CALA
|
49.1 M | - | -10.95 % | $ 876 K | ||
|
Molecular Templates
MTEM
|
10.1 M | - | -23.43 % | $ 495 K | ||
|
Oncorus
ONCR
|
8.55 K | - | -8.54 % | $ 3.19 M | ||
|
BioXcel Therapeutics
BTAI
|
15.4 M | $ 0.07 | 9.81 % | $ 855 K | ||
|
Novan
NOVN
|
26.2 M | - | -24.84 % | $ 2.64 M | ||
|
CohBar
CWBR
|
5.31 M | - | -15.44 % | $ 2.2 M | ||
|
NeuBase Therapeutics
NBSE
|
6.27 M | - | -1.56 % | $ 12.3 M | ||
|
Epizyme
EPZM
|
126 M | - | - | $ 249 M | ||
|
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | ||
|
Scopus BioPharma
SCPS
|
3.8 M | - | -48.37 % | $ 3.71 M | ||
|
Nabriva Therapeutics plc
NBRV
|
4.1 M | - | - | $ 4.55 M | ||
|
Annovis Bio
ANVS
|
51.8 M | $ 0.71 | -3.81 % | $ 14.6 M | ||
|
scPharmaceuticals
SCPH
|
210 M | - | - | $ 218 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
73.7 M | - | - | $ 105 M | ||
|
Athersys
ATHX
|
8.07 M | - | 3.77 % | $ 22.4 M | ||
|
Global Blood Therapeutics
GBT
|
1.82 B | - | - | $ 4.62 B | ||
|
Inozyme Pharma
INZY
|
297 M | - | - | $ 207 M | ||
|
NanoString Technologies
NSTG
|
459 M | - | -37.43 % | $ 5.1 M | ||
|
Humanigen
HGEN
|
12.5 M | - | -81.12 % | $ 4.28 M | ||
|
CNS Pharmaceuticals
CNSP
|
1.06 M | $ 3.56 | -9.07 % | $ 1.58 M | ||
|
Sorrento Therapeutics
SRNE
|
746 M | - | -29.58 % | $ 126 M | ||
|
Surface Oncology
SURF
|
40.7 M | - | - | $ 59.7 M | ||
|
Sierra Oncology
SRRA
|
288 M | - | -0.05 % | $ 1.34 B | ||
|
Vaccinex
VCNX
|
2.96 M | - | -61.37 % | $ 654 K | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
18.7 M | - | -19.68 % | $ 18.4 M | ||
|
Jounce Therapeutics
JNCE
|
47.5 M | - | - | $ 98.4 M | ||
|
Cocrystal Pharma
COCP
|
11.4 M | $ 0.93 | -4.11 % | $ 10.5 M | ||
|
Fortress Biotech
FBIO
|
77.8 M | $ 1.89 | 6.78 % | $ 52.7 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Longeveron
LGVN
|
16.9 B | $ 1.65 | -9.34 % | $ 29 B | ||
|
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | ||
|
Immunic
IMUX
|
145 M | $ 7.0 | -5.28 % | $ 1.09 B | ||
|
Immunovant
IMVT
|
6.49 B | $ 31.74 | -2.4 % | $ 5.79 B | ||
|
Mersana Therapeutics
MRSN
|
60 M | - | - | $ 3.56 B | ||
|
Akari Therapeutics, Plc
AKTX
|
8.08 B | $ 6.83 | 1.71 % | $ 460 B | ||
|
MediWound Ltd.
MDWD
|
131 M | $ 13.59 | 0.33 % | $ 370 M | ||
|
CymaBay Therapeutics
CBAY
|
3.43 B | - | - | $ 3.45 B | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
261 M | - | - | $ 384 M | ||
|
Keros Therapeutics
KROS
|
513 M | $ 11.04 | -3.07 % | $ 411 M |